Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 3/20 | 0.59 |
| ▸ | NPY4R | P50391 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405009 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29404011 | 0.98 | GHSR (0.60) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL29414549 | 0.95 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL30490002 | 0.94 | GHSR (0.66) | GHSR | |
| SCHEMBL30490007 | 0.94 | GHSR (0.66) | GHSR | |
| SCHEMBL31157965 | 0.93 | UTS2R (0.58) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL31404052 | 0.92 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29508679 | 0.91 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29896929 | 0.91 | GHSR (0.63) | GHSRNPY1RNPY2RNPY4ROPRM1 | |
| SCHEMBL31253374 | 0.91 | GHSR (0.58) | GHSRUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |